Comprehensive reviews of the literature related to management and diagnosis of pheochromocytoma are available elsewhere.

In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

Spear and Griswald 9 reported the first case of a fall in blood pressure after the administration of dibenamine (N, N-dibenzyl-β-chloroethylamine) to a patient who proved at operation to have a ...

Patients with optic disc edema are often brought to the attention of ophthalmologists either as referrals from internists or as a first consultation by a patient with visual symptoms. The ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

About one-third of pheochromocytoma cases are inherited or genetic. Genetic screening can provide critical information about the patient's chance of recovery. Comprehensive screening for family ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

A pheochromocytoma is a tumor that produces adrenaline ... Usually, it presents with no apparent signs or symptoms, unless the adrenal glands are producing excessive hormones (such as cortisol and ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.